橡楚编辑部 8/13/2026 50 min read
Medical silicone parts are indispensable core components in the medical device field due to their excellent biocompatibility, disinfection resistance, non-toxic and odorless properties. This article sorts out the core performance standards, compliant production processes of medical silicone parts, as well as their typical applications in respiratory, surgical and nursing medical devices, helping practitioners clearly understand product selection and quality control points to ensure the safety and stability of clinical use.
Liquid Silicone Rubber (LSR) is a high-purity, two-part platinum-cured elastomer that has become the dominant material for critical medical silicone parts (医用硅胶配件) across diagnostic, therapeutic, and surgical device segments. Unlike commodity elastomers such as polyvinyl chloride (PVC) or natural rubber, medical-grade LSR undergoes stringent manufacturing controls to eliminate leachable additives, endotoxins, and microbial contaminants, making it suitable for both short-term (≤24 hours) and long-term (≥30 days) patient contact applications.
Global demand for medical silicone parts is projected to reach $12.7 billion by 2028, driven by the expansion of minimally invasive surgery, home healthcare devices, and wearable diagnostic tools, according to Grand View Research. This growth is underpinned by the unique combination of biocompatibility, mechanical stability, and processing flexibility that LSR offers, properties that cannot be replicated by alternative materials for high-risk medical use cases. This article provides a systematic analysis of the core performance metrics of medical silicone parts, regulatory validation frameworks, leading application segments, and advanced manufacturing innovations shaping the future of the field.
Medical silicone parts are engineered to meet strict performance thresholds tailored to their intended use environment, ranging from sterile surgical fields to chronic implantable settings. The following sections break down the non-negotiable performance attributes that distinguish medical-grade LSR components from industrial silicone counterparts.
Biological safety is the foundational requirement for any medical silicone part, as direct or indirect patient contact carries inherent risks of toxic reaction, inflammation, or infection. All medical-grade LSR formulations for clinical use must comply with ISO 10993 (Biological Evaluation of Medical Devices) and USP Class VI testing protocols, the two most widely recognized global standards for biomaterial safety.
Table 1: Key Biological Testing Requirements for Medical Silicone Parts
For implantable medical silicone parts intended for long-term (>30 days) contact with internal tissue, additional testing for hemocompatibility (ISO 10993-4), subchronic toxicity (ISO 10993-11), and carcinogenicity (ISO 10993-3) is mandatory. High-purity platinum-cured LSR inherently meets these requirements, as it contains no phthalates, PVC plasticizers, or natural rubber latex proteins that are common triggers of adverse patient reactions. Unlike peroxide-cured silicone, which leaves residual benzoic acid byproducts, platinum-cured LSR has extractable levels of <0.1% by weight, eliminating the risk of leachable contaminants entering the patient’s bloodstream or tissue.
Medical silicone parts are often exposed to extreme mechanical stress, temperature fluctuations, and chemical agents during sterilization, storage, and clinical use, requiring exceptional durability across a wide range of operating conditions.
The core mechanical properties of medical-grade LSR are outlined below:
Table 2: Sterilization Compatibility of Medical Elastomers
Medical silicone parts also exhibit exceptional chemical resistance to common clinical agents, including isopropyl alcohol, povidone-iodine, bleach, and most intravenous (IV) medications. They have low water absorption (<0.1% by weight after 30 days of immersion in saline), preventing microbial colonization and material swelling in fluid-exposed applications such as wound drains and infusion pump tubing.
Beyond basic mechanical and biological properties, medical silicone parts can be formulated to meet unique functional requirements for diagnostic and wearable device applications.
For optical applications such as endoscope lenses, ophthalmic surgical tools, and phototherapy device components, LSR can be formulated with >94% light transmittance in the visible spectrum (400 to 700 nm) and <1% haze, matching the optical clarity of polycarbonate while offering superior impact resistance and biocompatibility for direct contact with ocular tissue. Custom pigmented LSR grades are also available for light-blocking medical silicone parts such as surgical light handles and diagnostic sensor housings, with customizable opacity for light wavelengths ranging from ultraviolet (UV) to near-infrared (NIR).
For wearable diagnostic and therapeutic devices, LSR can be compounded with conductive fillers such as silver particles, carbon nanotubes, or graphene to create electrically conductive medical silicone parts with volume resistivity ranging from 10⁻³ Ω·cm (high conductivity for ECG electrode contacts) to 10⁹ Ω·cm (static dissipative for surgical device housings). Unlike rigid conductive polymers, conductive LSR retains 80% of its electrical conductivity after 10,000 stretching cycles to 50% elongation, making it ideal for flexible wearable sensors that conform to patient skin during movement. Low-dielectric LSR grades (dielectric constant 2.7 to 3.2 at 1 MHz) are also used for high-frequency medical device components such as RFID tag housings and MRI coil insulation, as they do not produce imaging artifacts or absorb RF energy during diagnostic scans.
The production and distribution of medical silicone parts are subject to rigorous regulatory oversight by global health authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and National Medical Products Administration (NMPA) in China. Unlike consumer-grade silicone products, medical silicone parts require full traceability from raw material batch to finished device, as well as documented validation of all manufacturing and sterilization processes.
All medical silicone parts intended for clinical use must be manufactured from FDA 21 CFR Part 177.2600 compliant LSR raw materials, which are produced in dedicated medical-grade manufacturing facilities with strict controls for contamination and batch consistency. Raw material suppliers must provide a Certificate of Analysis (CoA) for each LSR batch, documenting:
Supply chain traceability is a non-negotiable requirement for medical silicone part manufacturers, with most regulatory bodies requiring a unique device identification (UDI) code for each finished component that links back to raw material batch numbers, production date, sterilization lot, and distribution records. For implantable medical silicone parts, many device manufacturers also require raw material suppliers to provide change notification 12 months in advance of any formulation or processing adjustments, as even minor changes to LSR composition can alter biocompatibility or mechanical performance in long-term implant applications.
Medical silicone parts are almost exclusively produced via liquid injection molding (LIM), a high-precision manufacturing process that allows for tight dimensional tolerances and zero flash production for critical components. All LIM processes for medical silicone parts must be validated in accordance with ISO 13485 quality management system requirements, with documented proof of process consistency across three consecutive production runs.
Key process validation parameters for LIM of medical silicone parts include:
Post-molding processing for medical silicone parts includes deflashing, post-curing, and cleaning, all of which must be validated to ensure no residual contaminants are introduced during secondary operations. Post-curing is typically performed at 200°C for 4 hours to remove residual volatile compounds and complete crosslinking, with post-cure time and temperature validated to ensure no change in part hardness or tensile strength outside of specified tolerance ranges.
Every batch of medical silicone parts must undergo a series of quality tests before release to the market, with test protocols tailored to the component’s intended use classification (Class I, II, or III per FDA regulations).
Routine quality control tests for medical silicone parts include:
The unique combination of biocompatibility, durability, and processing flexibility has made medical silicone parts the preferred choice for a wide range of clinical use cases, from disposable surgical supplies to chronic implantable devices. The following sections highlight the highest-volume and most innovative applications of medical silicone parts in modern healthcare.
Minimally invasive surgery (MIS) is one of the fastest-growing segments of medical device development, with 23 million MIS procedures performed globally in 2023, according to the World Health Organization. Medical silicone parts are critical components of nearly all MIS and anesthesiology devices, as they offer the flexibility and biocompatibility required for access through small incisions or natural body orifices.
Key applications in this segment include:
Medical silicone parts are the gold standard for long-term implantable devices, as they exhibit minimal inflammatory response and stable performance over decades of implantation in the human body. The global market for silicone implantable devices is projected to reach $6.8 billion by 2027, driven by rising demand for cardiac, orthopedic, and reconstructive implants.
Leading implant applications include:
The rapid growth of home healthcare and remote patient monitoring has created new demand for flexible, skin-safe medical silicone parts for wearable diagnostic devices. Unlike traditional hospital-based devices, wearables must be comfortable for 24/7 wear, conform to dynamic body movement, and withstand repeated exposure to sweat, soap, and water.
Key applications in this segment include: